August 27, 2026

BioXcel Therapeutics, Inc.

Track this case

Case Number:

1:26-bk-11360

Court:

Delaware

Nature of Suit:

Firms

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. October 21, 2026

    BioXcel Gets Nod For $125M Bankruptcy Sale To Teva

    A Delaware bankruptcy judge Wednesday gave the OK to artificial intelligence-powered pharmaceutical group BioXcel to proceed with a $125 million sale to Israeli drugmaker Teva Pharmaceuticals, and allowed the debtor to send its Chapter 11 plan for a creditor vote.

7 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login